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Review question/objective 
The objective of this review is to identify the effectiveness of the interventions in preventing 
progression of pre-frailty and frailty in older adults. 
More specifically, the review questions are: 
- What is the effectiveness of interventions in preventing or reducing frailty in older adults? 
- How does effectiveness vary with degree of frailty?  
- Are there factors that influence the effectiveness of interventions? 
- What is the economic feasibility of interventions for pre-frailty and frailty?   
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Background 
Frailty is an age-related state of high vulnerability to adverse health outcomes after a stressor event1-6, 
predisposing the individuals to falls and fractures, disability, dependency, hospitalization and 
institutional placement, and ultimately death.1 It can be preceded by, but also occurs in the absence of, 
chronic disease.3,5,7 According to some authors, this clinical condition results from decrease in 
reserves across multiple physiological systems that are normally responsible for healthy adaptation to 
stress.1,8,9 Alternatively, it is considered that frailty is due to the critical accumulation of dysregulation in 
important signaling pathways and subsequent depletion of homeostatic reserve and resiliency.1,10,11 
Other authors describe this state of increased vulnerability as associated with a reduced capacity to 
compensate aging-related molecular and cellular damage.2 Independently of pathophysiological 
conceptualization, it is assumed that frailty is a dynamic process that leads to a spiraling decline in 
various functional domains that exacerbates the risk of geriatric syndromes.1,3,5,6 
The phenotypic markers of frailty include global weakness with low muscle strength (e.g. poor grip 
strength), overall slowness (particularly in gait), decreased balance and mobility, fatigability or 
exhaustion, low physical activity and involuntary weight loss.1,3,5,8 For diagnostic purposes, at least 
three of these components must be observed.8 The presence of only one or two of them is considered 
as an indicator of the state of pre-frailty. From a broader perspective, it is assumed that frailty can also 
manifest through cognitive impairment,12-16 although, according to evidence, the decline in cognition is 
very selective, being limited to executive functions, attention, verbal fluency and processing of speed. 
It is also well documented that frail elderlies manifest some impairment in activities of daily  living and 
report significant reduction in quality of life.12,17 Furthermore, recent studies have shown that frailty may 
be related to mood change,16,18 although the nature of this association, as well as its relevance to the 
frailty construct, needs to be clarified.17 
Regarding the prevalence of frailty, systematic comparison of numerous studies19 shows that frailty in 
community-dwelling adults aged 65 and over varies from 4% to 17%. In case of pre-frailty, the 
frequency varies between 19% and 53% in different studies.19 The differences in estimates due to 
differences in the operational definition of frailty (based on physical markers or incorporating a broader 
multidimensional approach) and study populations (e.g. the results of epidemiological studies can be 
affected by demographic variables, such as age and gender, as well as the presence of chronic 
disease or other comorbid conditions).  
Because of the frequency of its occurrence and the severity of its consequences, frailty is seen as a 
threatening condition for older adults, requiring attention from health care professionals, social care 
practitioners, researchers and policy-makers.3,6,19 The implications of the involvement of these agents 
can be observed at various levels, with issues related to improving prognosis and preventing the 
progression from pre-frail to frail being of the greatest interest and relevance. In relations to 
interventions, attempts to manage adverse consequences of frailty are often focused on minimization 
of risks of disability and dependency, or on the treatment of underlying conditions and symptoms. For 
complementary approaches, frailty management involves the development of coping strategies 
necessary to control potential stress factors or to minimize their impact.3,20 So far, various types of 
intervention have been proposed, among which are physical activity, psychosocial intervention, health 
and social care provision, cognitive stimulation, nutrition, medication/medical maintenance and 
adherence focused interventions, and multifactorial intervention. The results of studies conducted in 
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this area have indicated that treating frailty in older adults is a realistic therapeutic goal.21-24 However, it 
is still hard to determine how effective these types of intervention are and how efficiency can be 
influenced by other factors, for example, severity of the clinical condition. Another issue requiring 
clarification is the effectiveness of interventions in terms of drug prescription and changes in analytical 
parameters.25,26 The focus of attention should also be directed to economic data, namely, costs relative 
to benefits and/or savings associated with implementing the interventions for pre-frailty and frailty.27 
A preliminary search of the JBI Database of Systematic Reviews and Implementation Reports, the 
Cochrane Database of Systematic Reviews, Prospero, CINAHL, and Medline has revealed that there 
are currently no systematic review (neither published nor in progress) on clinical/medical and 
economic effectiveness of interventions to prevent or reduce frailty in older adults. 
Therefore, it is necessary for a systematic review to be conducted to examine the effectiveness of the 
interventions to prevent the progression of pre-frailty and frailty in older adults, involving a critical 
analysis based on scientific evidence. 
Keywords 
frail elderly; pre-frailty; frailty 
Inclusion criteria 
Types of participants 
This review will consider studies that include older adults (female and male) aged 65 years and over, 
explicitly identified as pre-frail or frail by the researchers or associated medical professionals according 
to a pre-specified scale or index, and who have received health care and support services in any type 
of setting (primary care, nursing homes, hospitals). 
This review will exclude studies that:  
- Include participants who have been selected because they have one specific illness 
- Consider people with a terminal diagnosis only. 
Types of intervention(s)/phenomena of interest 
The clinical/medical component of the review will consider studies that evaluate any type of 
interventions to prevent the progression of pre-frailty and frailty in older adults. These interventions will 
include, but will not be limited to, physical activity, multifactorial intervention, psychosocial intervention, 
health and social care provision, and cognitive, nutrition or medication/medical maintenance and 
adherence focused interventions. 
The economic component of the review will consider studies that have performed any type of health 
economic analysis of interventions to prevent the progression of pre-frailty and frailty in older adults.  
The comparator for both clinical/medical and economic components will be implementing usual care, 
alternative therapeutic interventions or no intervention. 
Types of outcomes 
Primary outcomes: 
- Frailty as indicated by any validated scale or measurement or index.    
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Secondary outcomes: 
i. Cognition, quality of life, quality-adjusted life year (QALY), activities of daily living (ADL), 
instrumental activities of daily living (IADL), caregiver burden, functional capacity, depression, 
self-perceived health and social engagement, as assessed by any validated scale or 
measurement or index.  
ii. Drugs and prescriptions, analytical parameters, falls and fractures, mortality, hospitalization, 
institutionalization and comorbidities. 
iii. Costs and/or costs relative to benefits and/or savings associated with implementing the 
interventions for pre-frailty and frailty. 
Types of studies 
The clinical / medical component of the review will consider randomized controlled trials (RCTs), 
non-randomized trials and quasi-experimental studies related to the effectiveness of interventions for 
pre-frailty and frailty for inclusion. In the absence of RCTs, non-randomized trials, quasi-experimental 
studies and other research designs of a quantitative nature, such as cohort studies, will be considered 
for inclusion. 
The economic component of the review will consider cost effectiveness, cost benefit, cost minimization 
or cost utility studies. Any quantitative study measuring clinical effectiveness that incorporates 
economic data will be considered. Studies where the effectiveness of the intervention on frailty 
measures is not measured will be excluded. 
Search strategy 
The search strategy aims to find both published and unpublished studies. A three-step search strategy 
will be utilized in this review. An initial limited search of MEDLINE via EBSCOhost Web and CINAHL 
will be undertaken followed by an analysis of text words contained in the title and abstract, and of the 
index terms used to describe the article. A second search using all identified keywords and index terms 
will then be undertaken across all included databases. Thirdly, the reference lists of all identified 
reports and articles will be searched for additional studies. Studies published in English, Portuguese, 
Spanish, Italian and Dutch will be considered for inclusion in this review. Studies published from 2001 
will be considered for inclusion in this review. This timeline was selected because 2001 is the year of 
publication of Fried’s paper8 that showed to be seminal for research on frailty. 
The databases to be searched include: 
CINAHL 
MEDLINE 
SCOPUS 
EMBASE 
Cochrane Central Register of Controlled Trials 
Scielo. 
The search for unpublished studies will include:  
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ProQuest Theses and Dissertations 
OpenGrey 
Banco de teses da CAPES (www.capes.gov.br) 
Dissertation Abstracts Online (e-Thos). 
Initial keywords to be used will be frailty, elder*, old*, intervention* 
During the process of conducting the search, various terminologies and spellings of the keywords will 
be taken into consideration as they might affect the identification of relevant studies. 
Assessment of methodological quality 
Quantitative papers selected for retrieval will be assessed by two independent reviewers for 
methodological validity prior to inclusion in the review using standardized critical appraisal instruments 
from the Joanna Briggs Institute Meta-Analysis of Statistics Assessment and Review Instrument 
(JBI-MAStARI) (Appendix I).  
Economic papers selected for retrieval will be assessed by two independent reviewers for 
methodological validity prior to inclusion in the review using standardized critical appraisal instruments 
from the Joanna Briggs Institute Analysis of Cost, Technology and Utilization Assessment and Review 
Instrument (JBI-ACTUARI) (Appendix I).  
Any disagreements that arise between the reviewers will be resolved through discussion, or with a third 
reviewer. 
Data extraction 
Quantitative data will be extracted from papers included in the review independently by two reviewers 
using the standardized data extraction tool from JBI-MAStARI (Appendix II). The data extracted will 
include specific details about the interventions, populations, study methods and outcomes of 
significance to the review question and specific objectives.  
Economic data will be extracted from papers included in the review using the standardized data 
extraction tool from JBI-ACTUARI (Appendix II). The data extracted will include specific details about 
the interventions, populations, study methods and outcomes of significance to the review question and 
specific objectives.  
If there is missing information or data that needs clarification, the authors of primary studies will be 
contacted. Any disagreements that arise between the reviewers will be resolved through discussion or 
with a third reviewer. 
Data synthesis 
Quantitative papers will, where possible, be pooled in statistical meta-analysis using JBI-MAStARI. All 
results will be subject to double data entry. Effect sizes expressed as odds ratio (for categorical data) 
and weighted mean differences (for continuous data) and their 95% confidence intervals will be 
calculated for analysis. Heterogeneity will be assessed statistically using the standard Chi-square. 
Plausible explanation for variations in treatment effects will be explored using subgroup analyses, 
whenever possible, based on frailty levels and settings included in the studies. Where statistical 
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pooling is not possible the findings will be presented in narrative form including tables and figures to 
aid in data presentation where appropriate. 
Economic findings will, where possible, be pooled using JBI-ACTUARI and presented in a tabular 
summary. Where this is not possible, findings will be presented in narrative form. 
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Appendix I: Appraisal instruments 
MAStARI appraisal instrument 
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ACTUARI appraisal instrument 
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Appendix II: Data extraction instruments 
MAStARI data extraction instrument 
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ACTUARI data extraction instrument 
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